OTC · CLVR
Clever Leaves Holdings Inc.
$0.01$0.00 (0.0%)
Clever Leaves Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.2% below the high.
Loading market information…
OTC · HTGMQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
HTG Molecular Diagnostics, Inc.’s next earnings report is currently expected on Nov 13, 2026, with estimated earnings per share of -$11.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HTG Molecular Diagnostics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HTG Molecular Diagnostics, Inc. operates as a life sciences company, specializing in the realm of precision medicine. They furnish specialized instruments, consumable products, and software applications engineered to automate the processing of samples and characterize a variety of molecular targets. Among their portfolio of molecular profiling panels are offerings like the HTG Transcriptome Panel, HTG EdgeSeq precision immuno-oncology panel, HTG EdgeSeq miRNA whole-transcriptome assay, HTG EdgeSeq DLBCL cell of origin assay EU, HTG EdgeSeq Oncology Biomarker Panel, HTG immune response panel, and the HTG mouse mRNA tumor response panel. The company handles direct distribution of its instruments and consumables across the United States and Europe, supplementing this with a network of distributors for other parts of Europe and global markets. Its customer base primarily includes biopharmaceutical corporations, academic research institutions, and molecular testing laboratories. Incorporated in 1997 and based in Tucson, Arizona, the entity was formerly known as HTG, Inc., adopting its current name, HTG Molecular Diagnostics, Inc., in March 2011. However, on June 5, 2023, HTG Molecular Diagnostics, Inc. initiated a voluntary Chapter 11 reorganization filing with the U.S. Bankruptcy Court for the District of Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:40 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2021 | Mar 29, 2022 | -$8.16-15.25% vs estimate | $2.88M-1.93% vs estimate |
|---|
| Q4 2020 | Mar 31, 2021 | -$9.63 | $1.44M |
|---|
| Q3 2020 | Sep 30, 2020 | -$13.47 | $1.78M |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01$0.00 (0.0%)
Clever Leaves Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.2% below the high.
$0.00$0.00 (0.0%)
Cue Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Biocept, Inc.’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
$0.00$0.00 (0.0%)
Brain Scientific Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Verde Science, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
$0.00$0.00 (0.0%)
Biostar Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
MedAvail Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
NexImmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
